ACIU vs. NRIX, DAWN, ANIP, RCUS, GYRE, SANA, ARDX, PRTA, OCUL, and SYRE
Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Nurix Therapeutics (NRIX), Day One Biopharmaceuticals (DAWN), ANI Pharmaceuticals (ANIP), Arcus Biosciences (RCUS), Gyre Therapeutics (GYRE), Sana Biotechnology (SANA), Ardelyx (ARDX), Prothena (PRTA), Ocular Therapeutix (OCUL), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.
AC Immune (NASDAQ:ACIU) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk.
In the previous week, AC Immune had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for AC Immune and 5 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.92 beat AC Immune's score of 0.48 indicating that Nurix Therapeutics is being referred to more favorably in the news media.
AC Immune has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.
AC Immune has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -264.84%. AC Immune's return on equity of -38.44% beat Nurix Therapeutics' return on equity.
AC Immune presently has a consensus target price of $12.00, suggesting a potential upside of 206.91%. Nurix Therapeutics has a consensus target price of $25.82, suggesting a potential upside of 17.68%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than Nurix Therapeutics.
AC Immune has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.
AC Immune received 195 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 74.68% of users gave Nurix Therapeutics an outperform vote while only 62.25% of users gave AC Immune an outperform vote.
51.4% of AC Immune shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 7.2% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
AC Immune beats Nurix Therapeutics on 12 of the 18 factors compared between the two stocks.
Get AC Immune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AC Immune Competitors List
Related Companies and Tools
